OverviewSuggest Edit

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases.

TypePublic
Founded2002
HQCambridge, US
Websitealnylam.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Jan 2019)1,065(+43%)
Job Openings95
Revenue (FY, 2018)$74.9 M
Share Price (Oct 2019)$81.9

Key People/Management at Alnylam Pharmaceuticals

Karen Anderson

Karen Anderson

SVP Chief Human Resources Officer
Barry Greene

Barry Greene

President
Yvonne Greenstreet

Yvonne Greenstreet

COO
Pushkal Garg

Pushkal Garg

Chief Medical Officer
Laurie Keating

Laurie Keating

SVP, General Counsel, and Secretary
John Maraganore

John Maraganore

CEO
Show more

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Cambridge, Zug and Windsor and Maidenhead
Cambridge, US (HQ)
300 Third St
Zug, CH
19 Dammstrasse
Windsor and Maidenhead, GB
Braywick Rd
Show all (3)

Alnylam Pharmaceuticals Financials and Metrics

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals's revenue was reported to be $74.91 m in FY, 2018
USD

Revenue (Q2, 2019)

44.7m

Gross profit (Q2, 2019)

40.4m

Gross profit margin (Q2, 2019), %

90.3%

Net income (Q2, 2019)

(219.5m)

EBIT (Q2, 2019)

(236.3m)

Market capitalization (17-Oct-2019)

9.1b

Closing stock price (17-Oct-2019)

81.9

Cash (30-Jun-2019)

1.1b

EV

8.0b
Alnylam Pharmaceuticals's current market capitalization is $9.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

74.9m

Cost of goods sold

1.8m

Gross profit

73.1m

Gross profit Margin, %

98%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

2.1m33.3m44.7m

Cost of goods sold

137.0k3.3m4.3m

Gross profit

1.9m29.9m40.4m

Gross profit Margin, %

93%90%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

53.2m75.2m180.9m193.6m645.4m420.1m

Accounts Receivable

17.9m18.8m

Inventories

3.9m9.7m16.6m21.7m24.1m

Current Assets

254.0m746.4m1.1b671.9m1.8b1.2b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

11.8m350.6m80.7m82.7m306.6m151.3m149.2m231.3m271.1m168.5m171.1m408.7m202.0m396.1m361.5m316.6m725.0m1.1b

Accounts Receivable

3.4m33.8m30.7m

Inventories

11.1m32.0m40.6m

Current Assets

199.2m674.1m665.1m643.0m1.1b1.0b1.0b1.1b888.1m747.6m597.2m960.7m993.4m1.7b1.5b1.3b1.4b2.1b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(89.2m)(360.4m)(290.1m)(410.1m)(490.9m)(761.5m)

Depreciation and Amortization

10.2m11.9m19.1m15.1m13.4m

Inventories

(22.6m)

Accounts Payable

1.8m8.8m1.7m10.1m(4.9m)15.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(56.9m)(250.9m)(295.0m)(339.0m)(50.8m)(122.6m)(76.8m)(103.0m)(193.1m)(297.2m)(107.3m)(225.7m)(348.6m)(141.2m)(304.8m)(550.1m)(181.9m)(401.4m)

Depreciation and Amortization

7.6m5.5m8.6m8.7m4.6m8.6m12.1m3.0m6.1m9.7m3.2m

Inventories

(10.4m)(7.1m)(15.0m)

Accounts Payable

(1.3m)121.0k(826.0k)15.5m(1.2m)14.3m347.0k(3.6m)(1.5m)(11.1m)(8.3m)(17.3m)(9.0m)(9.7m)(650.0k)(17.1m)26.4m
USDY, 2019

EV/EBIT

-33.9 x

EV/CFO

79.8 x

Financial Leverage

1.5 x
Show all financial metrics

Alnylam Pharmaceuticals Online and Social Media Presence

Embed Graph

Alnylam Pharmaceuticals Blogs

RNAi Roundtable: Givosiran, in Development for the Treatment of Acute Hepatic Porphyria

On October 7, 2019, we hosted an online RNAi Roundtable to review the progress with givosiran, an RNAi therapeutic in development for the treatment of acute hepatic porphyria. Access the replay View the presentation Read the transcript Akin Akinc, Ph.D., General Manager, Givosiran Srikanth Nagalla,.…

RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis

On September 16, 2019, we hosted an online RNAi Roundtable to review the progress with patisiran and vutrisiran, RNAi therapeutics in development for the treatment of transthyretin-mediated amyloidosis. Access the replay View the presentation ONPATTRO® (patisiran) is approved in the U.S. and Canada …

New Evidence Demonstrating Significant Association of V122I TTR Gene Mutation with Clinical Diagnosis of Polyneuropathy

We presented new results from an analysis of the UK Biobank demonstrating a significant association of the V122I mutation, a highly prevalent mutation in the transthyretin (TTR) gene, with a clinical diagnosis of polyneuropathy. These results were presented at the Heart Failure Society of America...…

New Clinical Results for Givosiran at ICPP

We presented additional results from the ENVISION Phase 3 study and the Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP), at the 2019 Interna…

Sixth Annual RNAi Roundtable Series

We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, clinical collaborators, and patients or patient advocates review recent progress in many of our late-stage pipeline programs and discuss the related disease areas. Click on any of the RNAi... The po…

New Clinical Research Findings for ONPATTRO® (patisiran) at EU-ATTR Amyloidosis Meeting

We presented results from a proteome-wide biomarker analysis of samples from the APOLLO Phase 3 study of ONPATTRO® (patisiran), as well as results from an analysis of the UK Biobank on clinical outcomes and medical history of individuals with the non-pathogenic transthyretin (TTR) ‘stabilizing’ T119…
Show more

Alnylam Pharmaceuticals Frequently Asked Questions

  • When was Alnylam Pharmaceuticals founded?

    Alnylam Pharmaceuticals was founded in 2002.

  • Who are Alnylam Pharmaceuticals key executives?

    Alnylam Pharmaceuticals's key executives are Karen Anderson, Barry Greene and Yvonne Greenstreet.

  • How many employees does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 1,065 employees.

  • What is Alnylam Pharmaceuticals revenue?

    Latest Alnylam Pharmaceuticals annual revenue is $74.9 m.

  • What is Alnylam Pharmaceuticals revenue per employee?

    Latest Alnylam Pharmaceuticals revenue per employee is $70.3 k.

  • Who are Alnylam Pharmaceuticals competitors?

    Competitors of Alnylam Pharmaceuticals include Celyad, Pernix Therapeutics and Sorrento Therapeutics.

  • Where is Alnylam Pharmaceuticals headquarters?

    Alnylam Pharmaceuticals headquarters is located at 300 Third St, Cambridge.

  • Where are Alnylam Pharmaceuticals offices?

    Alnylam Pharmaceuticals has offices in Cambridge, Zug and Windsor and Maidenhead.

  • How many offices does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 3 offices.